Spiliotis J D, Halkia E, Boumis V A, Vassiliadou D T, Pagoulatou A, Efstathiou E
Int J Surg Oncol. 2014;2014:987475. doi: 10.1155/2014/987475.
The combined treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a rigorous surgical treatment, most suitable for young and good performance status patients. We evaluated the outcomes of elderly patients undergoing CRS and HIPEC for peritoneal carcinomatosis with careful perioperative care.
All consecutive patients 70 years of age or older who were treated for peritoneal carcinomatosis over the past five years were included. Primary outcomes were perioperative morbidity and mortality. Secondary outcomes were disease-free survival and overall survival.
From a pool of 100 patients, with a diagnosis of PC who underwent CRS and HIPEC in our center, we have included 30 patients at an age of 70 years or older and the results were compared to the patients younger than 70 years. The total morbidity rate was 50% versus 41.5% in the group younger than 70 years (NSS).The mortality rate was 3.3% in the elderly group versus 1.43%in the younger group (NSS). Median overall survival was 30 months in the older group versus 38 months in the younger group.
Cytoreductive surgery and HIPEC for peritoneal carcinomatosis may be safely performed with acceptable morbidity in selected elderly patients.
细胞减灭术联合热灌注腹腔化疗治疗腹膜癌病是一种严格的外科治疗方法，最适合年轻且身体状况良好的患者。我们通过精心的围手术期护理，评估了接受细胞减灭术和热灌注腹腔化疗治疗腹膜癌病的老年患者的预后。
纳入过去五年中所有接受腹膜癌病治疗的70岁及以上的连续患者。主要结局是围手术期发病率和死亡率。次要结局是无病生存期和总生存期。
在我们中心，从100例诊断为腹膜癌病并接受细胞减灭术和热灌注腹腔化疗的患者中，我们纳入了30例70岁及以上的患者，并将结果与70岁以下的患者进行了比较。总发病率在70岁以下组为41.5%，在老年组为50%（无显著性差异）。老年组死亡率为3.3%，年轻组为1.43%（无显著性差异）。老年组中位总生存期为30个月，年轻组为38个月。
对于选定的老年患者，细胞减灭术和热灌注腹腔化疗治疗腹膜癌病可以安全进行，发病率可接受。
